Methods for treating lysosomal acid lipase deficiency in patients
AssigneeAlexion Pharmaceuticals, Inc.
InventorAnthony Quinn
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.
Claims7
A method of treating a human patient suffering from a lysosomal acid lipase (LAL) deficiency, comprising administering to the human patient safe and effective amounts of recombinant human LAL, wherein the administration of safe and effective amounts of recombinant human LAL comprises:
- a) administering an initial dosage in an amount at 1 mg LAL/kg body weight one or more times, followed by
- b) administering a subsequent dosage in an amount of 3 mg LAL/kg body weight one or more times.
Dependencies are inferred from the claim text.